a phase ii study conducted in our department revealed that mitoxantrone was active to malignant lymphoma refractory to conventional agents including adriamycin : 6 ( 33 % ) of 18 patients responded to the agent .
C0026259
mitoxantrone
C0024299
malignant lymphoma